Recombinant High-Density Lipoprotein Formulations
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Esad Vucic & Robert S. Rosenson
- چاپ و سال / کشور: 2010
Description
High-density lipoprotein cholesterol (HDL-C)as emerged as a biomarker of residual cardiovascular disease (CVD) risk in high-risk patients treated with lowdensity lipoprotein cholesterol (LDL-C)-lowering therapies inclusive of inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase. The evidence for increasing low levels of HDLC is sparse, and the available data are confounded by metabolic interactions between elevated very low-density lipoprotein (VLDL) and LDL particle oncentrations.Despite these limitations, there has been widespread interest in novel strategies that target HDL. One such path has been the development of recombinant HDL formulations that mimic the pre-beta fraction of native HDL, which is the main HDL subclass that mediates cholesterol efflux from lipid-laden macrophages. Various recombinant HDL formulations (apolipoprotein A-1 [apoA- ]-bound phospholipid disks or delipidated HDL particles, mutant apoA-1 proteins, and apoA-1 imetic peptides) have been investigated in animal studies and some human trials. However,these HDL-modifying therapies require evaluation in clinical trials of atherosclerosis and CVD events. This review presents our current knowledge on novel recombinant atherosclerotic CVD events.
Curr Atheroscler Rep (2011) 13:81–87 DOI 10.1007/s11883-010-0141-4 Published online: 6 November 2010
